SCHEMBL6981578

SCHEMBL6981578

CN(CC(=O)N1CCN(c2ccccc2Cl)CC1)C(=O)[C@H]1O[C@@H]1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.47
HTR7 P34969 1/20 0.46
AKR1C3 P42330 1/20 0.44
TSHR P16473 2/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
NOTUM Q6P988 1/20 0.41
PARP1 P09874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6978386 0.78 KMT2A (0.49) GRM5HTR7AKR1C3TSHRMEN1
SCHEMBL6978390 0.78 KMT2A (0.49) GRM5HTR7AKR1C3TSHRMEN1
SCHEMBL6978355 0.76 GFER (0.55) GRM5HTR7AKR1C3TSHRMEN1
SCHEMBL6978349 0.76 GFER (0.55) GRM5HTR7AKR1C3TSHRMEN1
SCHEMBL6978571 0.74 KMT2A (0.44) GRM5HTR7AKR1C3TSHRMEN1
SCHEMBL6981707 0.73 SMN1; SMN2 (0.43) GRM5HTR7AKR1C3TSHRMEN1
SCHEMBL6984624 0.72 GRM5 (0.41) GRM5HTR7AKR1C3TSHRMEN1
SCHEMBL6979020 0.72 SMN1; SMN2 (0.49) GRM5AKR1C3MEN1KMT2ASMN1; SMN2
SCHEMBL6979028 0.72 SMN1; SMN2 (0.49) GRM5AKR1C3MEN1KMT2ASMN1; SMN2
SCHEMBL12781876 0.71 TSHR (0.61) GRM5HTR7AKR1C3TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed